India [October 07, 2025] – Terumo India, the Indian arm of Terumo Corporation (TSE: 4543), a global leader in medical technology, announced the launch of FineCross™ M3 Coronary Micro-Guide Catheter in India.
The latest-generation catheter enhances percutaneous coronary intervention (PCI) procedures by delivering superior crossability, guidewire support, and navigability in complex coronary lesions.
Built on Terumo's trusted global expertise, FineCross™ M3 empowers physicians to perform safer and more efficient interventions, improving outcomes for patients with challenging coronary anatomies.
Addressing the Growing Burden of CAD
With coronary artery disease (CAD) continuing to be the leading cause of death in India, and a rising number of patients presenting with complex lesions, there is an urgent need for advanced interventional tools.
FineCross™ M3 is designed to help cardiologists perform more predictable, efficient, and safer procedures, improving both clinical outcomes and procedural confidence.
Leadership Perspective
Mr. Shishir Agarwal, President and Managing Director, Terumo India, said:
"Innovation at Terumo India is always guided by enabling physicians to deliver the best possible care to patients. With the launch of FineCross™ M3, we are proud to bring a globally trusted advancement in interventional cardiology to India. This milestone reflects our commitment to strengthening cardiovascular care and our promise of 'Unwavering Commitment to Patients'."
Advanced Design for Complex Interventions
FineCross™ M3 integrates Terumo's engineering excellence with enhanced design features to address real-world PCI challenges.
Key features include:
- 1.7 Fr tapered distal tip for superior lesion crossability
- 15 cm floppy distal segment for exceptional trackability in tortuous vessels
- Tapered stainless-steel braided shaft for improved pushability and control
- Next-generation hydrophilic coating for enhanced lubrication and durability
- PTFE inner layer with radiopaque marker for smooth delivery and precise visualization
Clinical Perspective
Mr. Nitin Stephen Abel, Senior Director, Terumo Interventional Systems, Terumo India, added:
"FineCross™ M3 represents more than a product launch—it reflects our continued focus on advancing cardiovascular care in India. Through globally trusted innovations, we aim to empower physicians to deliver better patient outcomes and create meaningful impact where it matters most."
Strengthening Interventional Portfolio
The launch of FineCross™ M3 further strengthens Terumo India's growing portfolio of advanced interventional solutions, reinforcing its role in shaping the future of cardiovascular care in India.
